BioNTech lung cancer drug extends survival versus chemotherapy ...Middle East

japan times - News
Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.

Hence then, the article about biontech lung cancer drug extends survival versus chemotherapy was published today ( ) and is available on japan times ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioNTech lung cancer drug extends survival versus chemotherapy )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News